Zahir Amoura

Paris, FR

Expertise in

conditions

Paris, FR

Overview

Zahir Amoura practices practicing medicine in Paris, France.

Mr. Amoura is highly rated in 44 conditions, according to our data. His clinical expertise encompasses Erdheim-Chester Disease, Non-Langerhans-Cell Histiocytosis, Reticulohistiocytoma, Splenectomy, and Kidney Transplant.

He is actively involved in clinical research, co-authoring 448 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

Paris, France

Other Locations

Clichy-sous-bois, France

Hospices Civils de Lyon
Lyon, France

Université Paris Est Créteil, Creteil, France

Ste Blandine Hospital, Nancy, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)

Enrollment Status: Completed

Publish Date: March 24, 2026

Intervention Type: Drug

Study Drugs: Steroid, Cyclophosphamide, Rituximab

Study Phase: Phase 3

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)

Enrollment Status: Completed

Publish Date: February 18, 2025

Intervention Type: Drug

Study Drugs: Rituximab, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper

Study Phase: Phase 3

Restauration of EBV Control in SLE Phase 1-2 Trial Evaluating Adoptive Transfer of Autologous EBV- Specific Cytotoxic T Lymphocytes in SLE Treatment

Enrollment Status: Terminated

Publish Date: March 25, 2022

Intervention Type: Biological

Study Drug: Autologous EBV specific CTL infusion

Study Phase: Phase 1/Phase 2

View 2 Less Clinical Trials

448 Total Publications

Assessment of EAPSDAS in critically ill patients with antiphospholipid syndrome.

Journal: EULAR rheumatology open

Published: August 28, 2026

View All 448 Publications

Frequently Asked Questions about Zahir Amoura

Is Zahir Amoura a top-rated expert for Erdheim-Chester Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Zahir Amoura is classified as an Elite expert for Erdheim-Chester Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Zahir Amoura participate in research or clinical trials?

Yes. Zahir Amoura has published 448 articles and abstracts on conditions like Erdheim-Chester Disease. You can view a list of Zahir Amoura's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Amoura's expertise for a condition

ConditionClose